\Altretm1.1Hbgl/\Altretm1.1Hbgl \Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal liver morphology |
J:342907
|
abnormal mitochondrial morphology |
J:342907
|
abnormal mitochondrial physiology |
J:342907
|
abnormal regulatory T cell physiology |
J:342907
|
decreased mitochondrial size |
J:342907
|
decreased regulatory T cell number |
J:342907
|
decreased T cell number |
J:342907
|
increased CD8-positive, alpha-beta T cell number |
J:342907
|
increased circulating alanine transaminase level |
J:342907
|
increased interleukin-17 secretion |
J:342907
|
increased liver tumor incidence |
J:342907
|
increased memory T cell number |
J:342907
|
increased regulatory T cell apoptosis |
J:342907
|
increased susceptibility to diet-induced hepatic steatosis |
J:342907
|
liver fibrosis |
J:342907
|
premature death |
J:342907
|
\Aregtm2c(EUCOMM)Hmgu/\Aregtm2c(EUCOMM)Hmgu \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
decreased blood oxygen saturation level |
J:224904
|
decreased body surface temperature |
J:224904
|
normal
immune system phenotype |
J:224904
|
increased susceptibility to Orthomyxoviridae infection |
J:224904
|
normal
mortality/aging |
J:224904
|
\B2mtm1Jae/\B2mtm1Jae \Foxp3sf\Otcspf/Y
involves: 129/Rl * 129S2/SvPas
|
abnormal immune system organ morphology |
J:20865
|
abnormal interleukin level |
J:20865
|
abnormal lymph node morphology |
J:20865
|
abnormal tumor necrosis factor level |
J:20865
|
anemia |
J:20865
|
decreased body size |
J:20865
|
decreased hematocrit |
J:20865
|
dermatitis |
J:20865
|
enlarged lymph nodes |
J:20865
|
enlarged spleen |
J:20865
|
increased CD4-positive, alpha-beta T cell number |
J:20865
|
increased IgG level |
J:20865
|
increased IgM level |
J:20865
|
increased immunoglobulin level |
J:20865
|
increased plasma cell number |
J:20865
|
\B9d2/Tgfb1tm1Flv/\B9d2+ \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
normal
growth/size/body region phenotype |
J:169839
|
normal
immune system phenotype |
J:169839
|
increased regulatory T cell number |
J:169839
|
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
normal
growth/size/body region phenotype |
J:169839
|
normal
immune system phenotype |
J:169839
|
increased regulatory T cell number |
J:169839
|
\Bcl2l11tm6.1Boui/\Bcl2l11tm6.1Boui \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased regulatory T cell number |
J:208318
|
\Becn1tm1Smoc/\Becn1tm1Smoc \Foxp3tm4(YFP/icre)Ayr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:306129
|
\Becn1tm1Smoc/\Becn1tm1Smoc \Zfp91tm1Smoc/\Zfp91tm1Smoc \Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:306129
|
\Cd4tm1Litt/\Cd4tm1Litt \Foxp3sf\Otcspf/Y
involves: 129/Rl * 129S2/SvPas
|
abnormal CD8-positive, alpha beta T cell morphology |
J:20865
|
abnormal cytokine secretion |
J:20865
|
abnormal immune system organ morphology |
J:20865
|
enlarged lymph nodes |
J:20865
|
increased IgG level |
J:20865
|
increased IgM level |
J:20865
|
increased interleukin-4 secretion |
J:20865
|
increased interleukin-6 secretion |
J:20865
|
increased tumor necrosis factor secretion |
J:20865
|
premature death |
J:20865
|
\Cd28tm1Ltu/\Cd28tm1Ltu \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal eyelid morphology |
J:194503
|
decreased locomotor activity |
J:194503
|
decreased regulatory T cell number |
J:194503
|
decreased T cell proliferation |
J:194503
|
enlarged lymph nodes |
J:194503
|
enlarged spleen |
J:194503
|
focal hair loss |
J:194503
|
hunched posture |
J:194503
|
increased activated T cell number |
J:194503
|
increased B cell number |
J:194503
|
increased susceptibility to autoimmune disorder |
J:194503
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:194503
|
ruffled hair |
J:194503
|
skin inflammation |
J:194503
|
skin lesions |
J:194503
|
\Cishtm1.1Cdon/\Cishtm1.1Cdon \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:204829
|
\Ctla4tm1Saka/\Ctla4tm1Saka \Foxp3tm1(cre)Saka/Y
involves: BALB/c
|
abnormal immunoglobulin level |
J:140085
|
abnormal liver morphology |
J:140085
|
abnormal regulatory T cell physiology |
J:140085
|
abnormal splenic cell ratio |
J:140085
|
enlarged heart |
J:140085
|
increased autoantibody level |
J:140085
|
increased IgE level |
J:140085
|
increased IgG level |
J:140085
|
increased inflammatory response |
J:140085
|
increased interferon-gamma secretion |
J:140085
|
increased interleukin-2 secretion |
J:140085
|
increased interleukin-4 secretion |
J:140085
|
increased regulatory T cell number |
J:140085
|
lung inflammation |
J:140085
|
lymph node hyperplasia |
J:140085
|
myocarditis |
J:140085
|
premature death |
J:140085
|
salivary gland inflammation |
J:140085
|
spleen hyperplasia |
J:140085
|
stomach inflammation |
J:140085
|
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi \Tg(Cd4-cre)1Cwi/0 \Foxp3sf/Y \Rag1tm1Mom/\Rag1+
mixed
|
decreased body weight |
J:348981
|
decreased inflammatory response |
J:348981
|
decreased regulatory T cell number |
J:348981
|
decreased T cell proliferation |
J:348981
|
enlarged spleen |
J:348981
|
thymus hypoplasia |
J:348981
|
\Dicer1tm1Bdh/\Dicer1tm1Bdh \Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ
|
blood vessel inflammation |
J:138683
|
enlarged lymph nodes |
J:138683
|
enlarged spleen |
J:138683
|
liver inflammation |
J:138683
|
lung inflammation |
J:138683
|
premature death |
J:138683
|
\Dicer1tm1Bdh/\Dicer1tm1Bdh \Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr
involves: 129S1/Sv * 129X1/SvJ
|
blood vessel inflammation |
J:138683
|
enlarged lymph nodes |
J:138683
|
enlarged spleen |
J:138683
|
liver inflammation |
J:138683
|
lung inflammation |
J:138683
|
premature death |
J:138683
|
\Droshatm1Litt/\Droshatm1.1Litt \Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal interferon-gamma secretion |
J:138683
|
abnormal interleukin-4 secretion |
J:138683
|
abnormal T cell activation |
J:138683
|
blood vessel inflammation |
J:138683
|
enlarged lymph nodes |
J:138683
|
enlarged spleen |
J:138683
|
increased CD8-positive, alpha-beta T cell number |
J:138683
|
increased leukocyte cell number |
J:138683
|
liver inflammation |
J:138683
|
lung inflammation |
J:138683
|
premature death |
J:138683
|
\Droshatm1Litt/\Droshatm1.1Litt \Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal interferon-gamma secretion |
J:138683
|
abnormal interleukin-4 secretion |
J:138683
|
abnormal regulatory T cell morphology |
J:138683
|
abnormal T cell activation |
J:138683
|
blood vessel inflammation |
J:138683
|
enlarged lymph nodes |
J:138683
|
enlarged spleen |
J:138683
|
increased CD8-positive, alpha-beta T cell number |
J:138683
|
increased leukocyte cell number |
J:138683
|
liver inflammation |
J:138683
|
lung inflammation |
J:138683
|
premature death |
J:138683
|
\Foxo1tm1Flv/\Foxo1tm1Flv \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
abnormal inflammatory response |
J:189962
|
abnormal regulatory T cell physiology |
J:189962
|
abnormal skin appearance |
J:189962
|
abnormal tail morphology |
J:189962
|
enlarged lymph nodes |
J:189962
|
enlarged spleen |
J:189962
|
hunched posture |
J:189962
|
increased CD4-positive, alpha-beta T cell number |
J:189962
|
increased CD8-positive, alpha-beta T cell number |
J:189962
|
increased interferon-gamma secretion |
J:189962
|
increased regulatory T cell number |
J:189962
|
increased T cell number |
J:189962
|
increased T cell proliferation |
J:189962
|
paralysis |
J:189962
|
premature death |
J:189962
|
\Foxo1tm1Flv/\Foxo1tm1Flv \Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/\Gt(ROSA)26Sor+ \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
normal
mortality/aging |
J:189962
|
\Foxo1tm1Flv/\Foxo1tm1Flv \Ifngtm1Ts/\Ifngtm1Ts \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ
|
normal
immune system phenotype |
J:189962
|
increased CD4-positive, alpha-beta T cell number |
J:189962
|
increased CD8-positive, alpha-beta T cell number |
J:189962
|
normal
mortality/aging |
J:189962
|
\Foxp3sf\Otcspf/Y
involves: 129/Rl
|
anemia |
J:20865
|
decreased body weight |
J:20865
|
decreased hematocrit |
J:20865
|
enlarged lymph nodes |
J:20865
|
enlarged spleen |
J:20865
|
increased CD4-positive, alpha-beta T cell number |
J:20865
|
postnatal lethality, incomplete penetrance |
J:20865
|
premature death |
J:20865
|
skin lesions |
J:20865
|
\Foxp3tm1.1Ayr/\Foxp3tm1.1Ayr \Mir146tm1.1Bal/\Mir146tm1.1Bal
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal lymphocyte physiology |
J:167922
|
blepharitis |
J:167922
|
conjunctivitis |
J:167922
|
decreased interferon-gamma secretion |
J:167922
|
dermatitis |
J:167922
|
increased regulatory T cell number |
J:167922
|
premature aging |
J:167922
|
\Foxp3tm1.1Ayr/Y \Rag1tm1Mom/\Rag1tm1Mom \Tg(TcraTcrb)425Cbn/0
Not Specified
|
normal
immune system phenotype |
J:97029
|
no abnormal phenotype detected |
J:97029
|
\Foxp3tm1.1Mal/\Foxp3tm1.1Mal \Lattm1.1Mal/\Lattm1.1Mal
involves: 129S2/SvPas * C57BL/6
|
abnormal regulatory T cell physiology |
J:131351
|
decreased regulatory T cell number |
J:131351
|
thymus hypoplasia |
J:131351
|
\Foxp3tm1Flv/\Foxp3+ \B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv \Tg(Cd4-cre)1Cwi/?
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased regulatory T cell number |
J:123547
|
\Foxp3tm1Kuch/? \Il6tm1Kopf/\Il6tm1Kopf
involves: 129S2/SvPas * C57BL/6
|
abnormal CD4-positive T cell differentiation |
J:123352
|
decreased circulating interleukin-6 level |
J:123352
|
decreased interleukin-17 secretion |
J:123352
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:123352
|
increased regulatory T cell number |
J:123352
|
\Foxp3tm1Tch/Y \Stat6tm1Gru/\Stat6tm1Gru
C.129-Stat6tm1Gru Foxp3tm1Tch
|
abnormal cytokine secretion |
J:117165
|
normal
immune system phenotype |
J:117165
|
increased circulating interferon-gamma level |
J:117165
|
increased eosinophil cell number |
J:117165
|
lethality at weaning, complete penetrance |
J:117165
|
normal
respiratory system phenotype |
J:117165
|
\Foxp3tm2.1(EGFP/cre)Shori/\Foxp3tm2.1(EGFP/cre)Shori \Pdcd1tm1Hon/\Pdcd1tm1Hon
involves: 129 * 129S2/SvPas * C57BL/6
|
premature death |
J:234397
|
\Foxp3tm2.1(EGFP/cre)Shori/Y \Pdcd1tm1Hon/\Pdcd1tm1Hon
involves: 129 * 129S2/SvPas * C57BL/6
|
decreased circulating lipase level |
J:234397
|
enlarged lymph nodes |
J:234397
|
enlarged spleen |
J:234397
|
increased effector memory T-helper cell number |
J:234397
|
increased susceptibility to autoimmune disorder |
J:234397
|
lymph node hyperplasia |
J:234397
|
pancreas atrophy |
J:234397
|
pancreas inflammation |
J:234397
|
premature death |
J:234397
|
spleen hyperplasia |
J:234397
|
\Foxp3tm2Ayr/\Foxp3+ \Rnf128tm1Cdon/\Rnf128tm1Cdon
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:160681
|
\Foxp3tm2Ayr/? \Zap70rps/\Zap70rps
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:211510
|
abnormal double-positive T cell morphology |
J:211510
|
abnormal regulatory T cell number |
J:211510
|
abnormal T cell differentiation |
J:211510
|
decreased CD4-positive, alpha-beta T cell number |
J:211510
|
decreased CD8-positive, alpha-beta T cell number |
J:211510
|
normal
immune system phenotype |
J:211510
|
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3+ \Gpr174tm1Cys/\Gpr174+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:222307
|
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3tm3(HBEGF/GFP)Ayr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:117743
|
abnormal dendritic cell physiology |
J:117743
|
bradykinesia |
J:117743
|
cachexia |
J:117743
|
conjunctivitis |
J:117743
|
decreased T cell number |
J:117743
|
dermatitis |
J:117743
|
enlarged spleen |
J:117743
|
increased dendritic cell number |
J:117743
|
increased susceptibility to autoimmune disorder |
J:117743
|
increased susceptibility to induced morbidity/mortality |
J:117743
|
liver inflammation |
J:117743
|
lung inflammation |
J:117743
|
lymph node inflammation |
J:117743
|
weight loss |
J:117743
|
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+ \Nr4a2tm1.1Pcn/\Nr4a2tm1.1Pcn
involves: 129S1/Sv * 129X1/SvJ
|
abnormal regulatory T cell morphology |
J:205658
|
abnormal regulatory T cell physiology |
J:205658
|
\Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr \Ikzf4tm1Djr/\Ikzf4tm1Djr
involves: 129S1/Sv * 129X1/SvJ
|
abnormal small intestine morphology |
J:294549
|
chronic inflammation |
J:294549
|
decreased regulatory T cell number |
J:294549
|
decreased small intestinal microvillus size |
J:294549
|
enlarged lymph nodes |
J:294549
|
enlarged spleen |
J:294549
|
glomerulonephritis |
J:294549
|
granulomatous inflammation |
J:294549
|
increased germinal center B cell number |
J:294549
|
increased immunoglobulin level |
J:294549
|
increased spleen B cell follicle number |
J:294549
|
increased spleen germinal center number |
J:294549
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:294549
|
increased T cell number |
J:294549
|
increased T follicular helper cell number |
J:294549
|
small intestinal inflammation |
J:294549
|
\Foxp3tm4(YFP/icre)Ayr/Y \Zfp91tm1Smoc/\Zfp91tm1Smoc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:306129
|
decreased regulatory T cell number |
J:306129
|
increased CD8-positive, alpha-beta T cell number |
J:306129
|
increased incidence of tumors by chemical induction |
J:306129
|
increased susceptibility to autoimmune disorder |
J:306129
|
increased susceptibility to induced colitis |
J:306129
|
\Foxp3tm9(EGFP/cre/ERT2)Ayr/\Foxp3+ \Il1r2tm1.1Epi/\Il1r2tm1.1Epi
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac
|
abnormal adaptive immunity |
J:347877
|
abnormal alpha-beta T cell number |
J:347877
|
increased CD4-positive, alpha-beta T cell number |
J:347877
|
increased IgG level |
J:347877
|
increased spleen germinal center size |
J:347877
|
increased T follicular helper cell number |
J:347877
|
\Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/\Gt(ROSA)26Sor+ \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
\Il10tm1Roer/\Il10tm1Roer \Foxp3tm4(YFP/icre)Ayr/Y
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal regulatory T cell physiology |
J:134513
|
abnormal type IV hypersensitivity reaction |
J:134513
|
colitis |
J:134513
|
decreased interleukin-10 secretion |
J:134513
|
lung inflammation |
J:134513
|
\Itchtm1.1Alta/\Itchtm1.1Alta \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal immunoglobulin level |
J:204685
|
abnormal interleukin secretion |
J:204685
|
abnormal lymph organ size |
J:204685
|
abnormal lymphopoiesis |
J:204685
|
abnormal regulatory T cell physiology |
J:204685
|
abnormal T-helper 2 cell differentiation |
J:204685
|
abnormal T-helper 2 physiology |
J:204685
|
decreased CD4-positive, alpha-beta T cell number |
J:204685
|
dermatitis |
J:204685
|
enlarged lymph nodes |
J:204685
|
enlarged spleen |
J:204685
|
normal
immune system phenotype |
J:204685
|
increased CD4-positive, alpha-beta T cell number |
J:204685
|
increased CD8-positive, alpha-beta T cell number |
J:204685
|
increased eosinophil cell number |
J:204685
|
increased IgA level |
J:204685
|
increased IgE level |
J:204685
|
increased IgG1 level |
J:204685
|
increased inflammatory response |
J:204685
|
increased interleukin-4 secretion |
J:204685
|
increased interleukin-5 secretion |
J:204685
|
increased interleukin-10 secretion |
J:204685
|
increased interleukin-13 secretion |
J:204685
|
increased interleukin-17 secretion |
J:204685
|
increased leukocyte cell number |
J:204685
|
increased regulatory T cell apoptosis |
J:204685
|
increased regulatory T cell number |
J:204685
|
lung inflammation |
J:204685
|
premature death |
J:204685
|
skin lesions |
J:204685
|
weight loss |
J:204685
|
\Itchtm1.1Alta/\Itchtm1.1Alta \Gt(ROSA)26Sortm1Hjf/\Gt(ROSA)26Sor+ \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:204685
|
increased inflammatory response |
J:204685
|
\Myd88tm1.1Medz/\Myd88tm1.1Medz \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:209373
|
\Nr4a1tm1Pcn/\Nr4a1tm1Pcn \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:205658
|
\Nr4a2tm1.1Pcn/\Nr4a2+ \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal regulatory T cell morphology |
J:205658
|
\Pgdtm1.1Pse/\Pgdtm1.1Pse \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal CD4-positive helper T cell morphology |
J:313817
|
abnormal regulatory T cell physiology |
J:313817
|
blepharitis |
J:313817
|
decreased body size |
J:313817
|
ear inflammation |
J:313817
|
enlarged lymph nodes |
J:313817
|
enlarged spleen |
J:313817
|
increased circulating interferon-gamma level |
J:313817
|
increased circulating interleukin-4 level |
J:313817
|
increased circulating interleukin-5 level |
J:313817
|
increased circulating interleukin-17 level |
J:313817
|
increased IgA level |
J:313817
|
increased IgD level |
J:313817
|
increased IgE level |
J:313817
|
increased IgG2a level |
J:313817
|
increased IgG3 level |
J:313817
|
increased IgM level |
J:313817
|
increased interferon-gamma secretion |
J:313817
|
increased susceptibility to type I hypersensitivity reaction |
J:313817
|
increased T cell number |
J:313817
|
premature death |
J:313817
|
\Pgdtm1.1Pse/\Pgdtm1.1Pse \Foxp3tm9(EGFP/cre/ERT2)Ayr/\Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
decreased tumor growth/size |
J:313817
|
\Socs1tm1Ayos/\Socs1tm1Ayos \Foxp3tm4(YFP/icre)Ayr/\Foxp3+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
blepharitis |
J:167922
|
conjunctivitis |
J:167922
|
dermatitis |
J:167922
|
increased regulatory T cell number |
J:167922
|
\Tg(Foxp3-HBEGF/EGFP)23.2Spar/0
involves: C57BL/6NCrl
|
abnormal pulmonary alveolus morphology |
J:125295
|
decreased regulatory T cell number |
J:125295
|
enlarged lymph nodes |
J:125295
|
enlarged spleen |
J:125295
|
epidermal hyperplasia |
J:125295
|
normal
immune system phenotype |
J:125295
|
increased inflammatory response |
J:125295
|
increased spleen red pulp amount |
J:125295
|
increased spleen white pulp amount |
J:125295
|
increased susceptibility to type IV hypersensitivity reaction |
J:125295
|
insulitis |
J:125295
|
lung inflammation |
J:125295
|
lymph node hyperplasia |
J:125295
|
skin inflammation |
J:125295
|